Richard Pascoe takes the helm at Histogen; Lonza COO steps up at CEO Richard Ridinger retires
→ Having handed off troubled microcap biotech Apricus Biosciences to Seelos Therapeutics via a merger, Richard Pascoe is moving on to his next CEO (and chairman) gig at Histogen. The regenerative medicine developer is anticipating data from a clinical trial in female hair loss this year, and the board likes Pascoe’s experience in both fundraising and regulatory dealings. Pascoe also appears to have a penchant for companies that get absorbed, including Somaxon Pharma, Ariad and Pfizer-acquired King Pharma.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.